Epidemiology and etiology of Alzheimer's disease: From genetic to non-genetic factors

Current Alzheimer Research

Volumn 10, Issue 8, 2013, Pages 852-867

  Jiang, Teng ^a   Yu, Jin Tai ^a,b,c   Tian, Yan ^b   Tan, Lan ^a,b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Alzheimer's disease; Environmental; Epidemiology; Etiology; Genetic; Risk factor

Indexed keywords

ALCOHOL; CHOLESTEROL; INHALATION ANESTHETIC AGENT; ORGANIC SOLVENT; PESTICIDE;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COFFEE; COGNITION; DEPRESSION; DIABETES MELLITUS; DYSLIPIDEMIA; ELECTROMAGNETIC FIELD; ENERGY METABOLISM; EXPOSURE; GENE; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; HEREDITY; HUMAN; HYPERTENSION; INCIDENCE; LIFESTYLE; MUTATION; NEOPLASM; NONHUMAN; OBESITY; OCCUPATIONAL EXPOSURE; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; SMOKING; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LIFE STYLE; MALE; MUTATION; PRESENILIN-1; PRESENILIN-2; PREVALENCE; RISK FACTORS;

EID: 84888062913     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990155     Document Type: Article

References (222)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 8(2): 131-68 (2012).
2. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 348(14): 1356-64 (2003).
3. Finder VH. Alzheimer's disease: a general introduction and pathomechanism. J Alzheimers Dis 22 (3): 5-19 (2010).
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-44 (1984).
5. Jack CR, Jr., Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 257-62 (2011).
6. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 270-9 (2011).
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 280-92 (2011).
8. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3(3): 186-91 (2007).
9. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503): 2112-7 (2005).
10. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60(8): 1119-22 (2003).
11. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 15(4): 169-73 (2001).
12. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 7(3): 137-52 (2011).
13. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63(2): 168-74 (2006).
14. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 287(3): 329-36 (2002).
15. Pedersen NL, Gatz M, Berg S, Johansson B. How heritable is Alzheimer's disease late in life? Findings from Swedish twins. Ann Neurol 55(2): 180-5 (2004).
16. Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L. Alzheimer's disease in Finnish twins. Lancet 347(9001): 573-8 (1996).
17. Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA, et al. Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci 52(2): M117-25 (1997).
18. Ashford JW, Mortimer JA. Non-familial Alzheimer's disease is mainly due to genetic factors. J Alzheimers Dis 4(3): 169-77 (2002).
19. Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 16(8): 865-73 (2007).
20. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68(4): 613-8 (2007).
21. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54(5): 713-20 (2007).
22. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65(1): 45-53 (2008).
23. Abraham R, Moskvina V, Sims R, Hollingworth P, Morgan A, Georgieva L, et al. A genome-wide association study for late-onset Alzheimer's disease using DNA pooling. BMC Med Genomics 1(44 (2008).
24. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 83(5): 623-32 (2008).
25. Poduslo SE, Huang R, Huang J, Smith S. Genome screen of lateonset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet 150B(1): 50-5 (2009).
26. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 84(1): 35-43 (2009).
27. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 41(2): 192-8 (2009).
28. Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, Fallon JH, et al. Hippocampal atrophy as a quantitative trait in a genomewide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One 4(8): e6501 (2009).
29. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41(10): 1088-93 (2009).
30. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41(10): 1094-9 (2009).
31. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303(18): 1832-40 (2010).
32. Naj AC, Beecham GW, Martin ER, Gallins PJ, Powell EH, Konidari I, et al. Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folatepathway abnormalities. PLoS Genet 6(9): (2010).
33. Lee JH, Cheng R, Barral S, Reitz C, Medrano M, Lantigua R, et al. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol 68(3): 320-8 (2011).
34. Sherva R, Baldwin CT, Inzelberg R, Vardarajan B, Cupples LA, Lunetta K, et al. Identification of novel candidate genes for Alzheimer's disease by autozygosity mapping using genome wide SNP data. J Alzheimers Dis 23(2): 349-59 (2011).
35. Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, et al. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet 7(2): e1001308 (2011).
36. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43(5): 429-35 (2011).
37. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43(5): 436-41 (2011).
38. Schellenberg GD, Montine TJ. The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol 124(3): 305-23 (2012).
39. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 7(7): 583-90 (2006).
40. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14(11): 992-1003 (2009).
41. Lahiri DK, Maloney B. The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp Gerontol 45(4): 291-6 (2010).
42. Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH. How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. Curr Alzheimer Res 4(2): 219-28 (2007).
43. Maloney B, Sambamurti K, Zawia N, Lahiri DK. Applying epigenetics to Alzheimer's disease via the latent early-life associated regulation (LEARn) model. Curr Alzheimer Res 9(5): 589-99 (2012).
44. Gauthier E, Fortier I, Courchesne F, Pepin P, Mortimer J, Gauvreau D. Environmental pesticide exposure as a risk factor for Alzheimer's disease: a case-control study. Environ Res 86(1): 37-45 (2001).
45. Blain PG. Aspects of pesticide toxicology. Adverse Drug React Acute Poisoning Rev 9(1): 37-68 (1990).
46. Corasaniti MT, Defilippo R, Rodino P, Nappi G, Nistico G. Evidence that paraquat is able to cross the blood-brain barrier to a different extent in rats of various age. Funct Neurol 6(4): 385-91 (1991).
47. Kimbrough RD, Gaines TB, Linder RE. The ultrastructure of livers of rats fed DDT and dieldrin. Arch Environ Health 22(4): 460-7 (1971).
48. Baldi I, Lebailly P, Mohammed-Brahim B, Letenneur L, Dartigues JF, Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol 157(5): 409-14 (2003).
49. Hayden KM, Norton MC, Darcey D, Ostbye T, Zandi PP, Breitner JC, et al. Occupational exposure to pesticides increases the risk of incident AD: the Cache County study. Neurology 74(19): 1524-30 (2010).
50. Gun RT, Korten AE, Jorm AF, Henderson AS, Broe GA, Creasey H, et al. Occupational risk factors for Alzheimer disease: a casecontrol study. Alzheimer Dis Assoc Disord 11(1): 21-7 (1997).
51. Tyas SL, Manfreda J, Strain LA, Montgomery PR. Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol 30(3): 590-7 (2001).
52. Kamel F, Hoppin JA. Association of pesticide exposure with neurologic dysfunction and disease. Environ Health Perspect 112(9): 950-8 (2004).
53. Li CY, Sung FC, Wu SC. Risk of cognitive impairment in relation to elevated exposure to electromagnetic fields. J Occup Environ Med 44(1): 66-72 (2002).
54. Davanipour Z, Tseng CC, Lee PJ, Sobel E. A case-control study of occupational magnetic field exposure and Alzheimer's disease: results from the California Alzheimer's Disease Diagnosis and Treatment Centers. BMC Neurol 7: 13 (2007).
55. Seidler A, Geller P, Nienhaus A, Bernhardt T, Ruppe I, Eggert S, et al. Occupational exposure to low frequency magnetic fields and dementia: a case-control study. Occup Environ Med 64(2): 108-14 (2007).
56. Garcia AM, Sisternas A, Hoyos SP. Occupational exposure to extremely low frequency electric and magnetic fields and Alzheimer disease: a meta-analysis. Int J Epidemiol 37(2): 329-40 (2008).
57. Qiu C, Fratiglioni L, Karp A, Winblad B, Bellander T. Occupational exposure to electromagnetic fields and risk of Alzheimer's disease. Epidemiology 15(6): 687-94 (2004).
58. Sobel E, Davanipour Z. Electromagnetic field exposure may cause increased production of amyloid beta and eventually lead to Alzheimer's disease. Neurology 47(6): 1594-600 (1996).
59. Noonan CW, Reif JS, Yost M, Touchstone J. Occupational exposure to magnetic fields in case-referent studies of neurodegenerative diseases. Scand J Work Environ Health 28(1): 42-8 (2002).
60. Maes A, Verschaeve L. Can cytogenetics explain the possible association between exposure to extreme low-frequency magnetic fields and Alzheimer's disease? J Appl Toxicol 32(2): 81-7 (2012).
61. Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology 19(4-5): 709-12 (1998).
62. Lindstrom K, Riihimaki H, Hanninen K. Occupational solvent exposure and neuropsychiatric disorders. Scand J Work Environ Health 10(5): 321-3 (1984).
63. Baker EL. A review of recent research on health effects of human occupational exposure to organic solvents. A critical review. J Occup Med 36(10): 1079-92 (1994).
64. Kukull WA, Larson EB, Bowen JD, McCormick WC, Teri L, Pfanschmidt ML, et al. Solvent exposure as a risk factor for Alzheimer's disease: a case-control study. Am J Epidemiol 141(11): 1059-71; discussion 72-9 (1995).
65. Vanderweyde T, Bednar MM, Forman SA, Wolozin B. Iatrogenic risk factors for Alzheimer's disease: surgery and anesthesia. J Alzheimers Dis 22(3): 91-104 (2010).
66. Zhang Y, Xu Z, Wang H, Dong Y, Shi HN, Culley DJ, et al. Anesthetics isoflurane and desflurane differently affect mitochondrial function, learning, and memory. Ann Neurol 71(5): 687-98 (2012).
67. Perucho J, Rubio I, Casarejos MJ, Gomez A, Rodriguez-Navarro JA, Solano RM, et al. Anesthesia with isoflurane increases amyloid pathology in mice models of Alzheimer's disease. J Alzheimers Dis 19(4): 1245-57 (2010).
68. Run X, Liang Z Gong CX. Anesthetics and tau protein: animal model studies. J Alzheimers Dis 22 (3): 49-55 (2010).
69. Le Freche H, Brouillette J, Fernandez-Gomez FJ, Patin P, Caillierez R, Zommer N, et al. Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. Anesthesiology 116(4): 779-87 (2012).
70. Avidan MS, Evers AS. Review of clinical evidence for persistent cognitive decline or incident dementia attributable to surgery or general anesthesia. J Alzheimers Dis 24(2): 201-16 (2011).
71. Bilotta F, Doronzio A, Stazi E, Titi L, Fodale V, Di Nino G, et al. Postoperative cognitive dysfunction: toward the Alzheimer's disease pathomechanism hypothesis. J Alzheimers Dis 22(3): 81-9 (2010).
72. Gasparini M, Vanacore N, Schiaffini C, Brusa L, Panella M, Talarico G, et al. A case-control study on Alzheimer's disease and exposure to anesthesia. Neurol Sci 23(1): 11-4 (2002).
73. Zuo C and Zuo Z. Spine Surgery under general anesthesia may not increase the risk of Alzheimer's disease. Dement Geriatr Cogn Disord 29(3): 233-9 (2010).
74. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol 121(3): 414-21 (1985).
75. Seitz DP, Shah PS, Herrmann N, Beyene J, Siddiqui N. Exposure to general anesthesia and risk of Alzheimer's disease: a systematic review and meta-analysis. BMC Geriatr 11: 83 (2011).
76. Schneider JA and Bennett DA. Where vascular meets neurodegenerative disease. Stroke 41(10): S144-6 (2010).
77. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 8(11): 1006-18 (2009).
78. Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke 39(1): 36-41 (2008).
79. Purandare N, Burns A, Morris J, Perry EP, Wren J, McCollum C. Association of cerebral emboli with accelerated cognitive deterioration in Alzheimer's disease and vascular dementia. Am J Psychiatry 169(3): 300-8 (2012).
80. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 60(12): 1707-12 (2003).
81. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348(13): 1215-22 (2003).
82. Launer LJ, Hughes TM, White LR. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol 70(5): 774-80 (2011).
83. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke 42(3): 722-7 (2011).
84. Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 134(Pt 2): 335-44 (2011).
85. Inaba M, White L, Bell C, Chen R, Petrovitch H, Launer L, et al. White matter lesions on brain magnetic resonance imaging scan and 5-year cognitive decline: the Honolulu-Asia aging study. J Am Geriatr Soc 59(8): 1484-9 (2011).
86. Prasad K, Wiryasaputra L, Ng A, Kandiah N. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. Dement Geriatr Cogn Disord 31(6): 431-4 (2011).
87. Blum S, Luchsinger JA, Manly JJ, Schupf N, Stern Y, Brown TR, et al. Memory after silent stroke: hippocampus and infarcts both matter. Neurology 78(1): 38-46 (2012).
88. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 103(49): 18727-32 (2006).
89. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, et al. Cerebrovascular lesions induce transient betaamyloid deposition. Brain 134(Pt 12): 3697-707 (2011).
90. Li J, Wang YJ, Zhang M, Fang CQ, Zhou HD. Cerebral ischemia aggravates cognitive impairment in a rat model of Alzheimer's disease. Life Sci 89(3-4): 86-92 (2011).
91. Wysocki M, Luo X, Schmeidler J, Dahlman K, Lesser GT, Grossman H, et al. Hypertension is associated with cognitive decline in elderly people at high risk for dementia. Am J Geriatr Psychiatry 20(2): 179-87 (2012).
92. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64(2): 277-81 (2005).
93. Elias PK, Elias MF, Robbins MA, Budge MM. Blood pressurerelated cognitive decline: does age make a difference? Hypertension 44(5): 631-6 (2004).
94. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322(7300): 1447-51 (2001).
95. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A and Blacker D. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology 22(5): 646-59 (2011).
96. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4(8): 487-99 (2005).
97. Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension 58(1): 22-8 (2011).
98. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology 61(12): 1667-72 (2003).
99. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev 8(2): 61-70 (2009).
100. Allan LM, Ballard CG, Allen J, Murray A, Davidson AW, McKeith IG, et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 78(7): 671-7 (2007).
101. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57(6): 789-94 (2005).
102. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26(4): 699-708 (2011).
103. Chang-Quan H, Hui W, Chao-Min W, Zheng-Rong W, Jun-Wen G, Yong-Hong L, et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a metaanalysis of longitudinal studies. Int J Clin Pract 65(12): 1295-305 (2011).
104. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37(5): 1165-70 (2006).
105. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology 72(20): 1727-34 (2009).
106. Duron E, Rigaud AS, Dubail D, Mehrabian S, Latour F, Seux ML, et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. Am J Hypertens 22(9): 1020-4 (2009).
107. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72(20): 1720-6 (2009).
108. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 67(6): 505-12 (2010).
109. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 65(8): 1066-73 (2008).
110. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid-and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58(1): 71-7 (2009).
111. Peila R, Rodriguez BL and Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51(4): 1256-62 (2002).
112. Ronnemaa E, Zethelius B, Sundelof J, Sundstrom J, Degerman-Gunnarsson M, Berne C, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 71(14): 1065-71 (2008).
113. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 52(6): 1031-9 (2009).
114. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75(9): 764-70 (2010).
115. Nomura S, Shouzu A, Taomoto K, Togane Y, Goto S, Ozaki Y, et al. Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan. J Atheroscler Thromb 16(6): 878-87 (2009).
116. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1): 29-38 (2012).
117. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13(11): 950-8 (2005).
118. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32(9): 1626-33 (2011).
119. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45(6): 1092-6 (1995).
120. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137(3): 149-55 (2002).
121. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16(5): 343-54 (2008).
122. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64(10): 1689-95 (2005).
123. Presecki P, Muck-Seler D, Mimica N, Pivac N, Mustapic M, Stipcevic T, et al. Serum lipid levels in patients with Alzheimer's disease. Coll Antropol 35(1) 115-20 (2011).
124. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80(1): 13-7 (2009).
125. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52(3): 346-50 (2002).
126. Sparks DL, Kryscio RJ, Connor DJ, Sabbagh MN, Sparks LM, Lin Y, et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener Dis 7(1-3): 183-6 (2010).
127. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74(12): 956-64 (2010).
128. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77(6): 556-63 (2011).
129. Serrano-Pozo A, Vega GL, Lutjohann D, Locascio JJ, Tennis MK, Deng A, et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord 24(3): 220-6 (2010).
130. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 967: 379-88 (2002).
131. Cai H, Cong WN, Ji S, Rothman S, Maudsley S, Martin B. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res 9(1): 5-17 (2012).
132. Warren MW, Hynan LS, Weiner MF. Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 29(1): 151-7 (2012).
133. Theodoropoulou A, Metallinos IC, Psyrogiannis A, Vagenakis GA, Kyriazopoulou V. Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. J Nutr Health Aging 16(5): 472-7 (2012).
134. Power DA, Noel J, Collins R, O'Neill D. Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement Geriatr Cogn Disord 12(2): 167-70 (2001).
135. Olsson T, Nasman B, Rasmuson S, Ahren B. Dual relation between leptin and cortisol in humans is disturbed in Alzheimer's disease. Biol Psychiatry 44(5): 374-6 (1998).
136. Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302(23): 2565-72 (2009).
137. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem 20(11): 831-9 (2009).
138. Kroner Z. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev 14(4): 373-9 (2009).
139. Alim I, Fry WM, Walsh MH, Ferguson AV. Actions of adiponectin on the excitability of subfornical organ neurons are altered by food deprivation. Brain Res 1330: 72-82 (2010).
140. Une K, Takei YA, Tomita N, Asamura T, Ohrui T, Furukawa K, et al. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur J Neurol 18(7): 1006-9 (2011).
141. Rutland-Brown W, Langlois JA, Thomas KE, Xi YL. Incidence of traumatic brain injury in the United States, 2003. J Head Trauma Rehabil 21(6): 544-8 (2006).
142. Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease? Nat Rev Neurosci 11(5): 361-70 (2010).
143. Shively S, Scher AI, Perl DP, Diaz-Arrastia R. Dementia Resulting From Traumatic Brain Injury: What Is the Pathology? Arch Neurol 69(10): 1245-51 (2012).
144. Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 74(7): 857-62 (2003).
145. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, et al. Head injury and the risk of AD in the MIRAGE study. Neurology 54(6): 1316-23 (2000).
146. Williams DB, Annegers JF, Kokmen E, O'Brien PC, Kurland LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology 41(10): 1554-7 (1991).
147. Mehta KM, Ott A, Kalmijn S, Slooter AJ, van Duijn CM, Hofman A, et al. Head trauma and risk of dementia and Alzheimer's disease: The Rotterdam Study. Neurology 53(9): 1959-62 (1999).
148. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 55(8): 1158-66 (2000).
149. Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45(3 Pt 1): 555-7 (1995).
150. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63(5): 530-8 (2006).
151. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology 75(1): 35-41 (2010).
152. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 75(1): 27-34 (2010).
153. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 69(5): 493-8 (2012).
154. Vilalta-Franch J, Lopez-Pousa S, Llinas-Regla J, Calvo-Perxas L, Merino-Aguado J, Garre-Olmo J. Depression subtypes and 5-year risk of dementia and Alzheimer disease in patients aged 70 years. Int J Geriatr Psychiatry 28(4): 341-50 (2013).
155. Wilson RS, Arnold SE, Beck TL, Bienias JL, Bennett DA. Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch Gen Psychiatry 65(4): 439-45 (2008).
156. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res 9(6): 628-45 (2012).
157. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 626(1): 64-71 (2010).
158. Behrens MI, Lendon C, Roe CM. A common biological mechanism in cancer and Alzheimer's disease? Curr Alzheimer Res 6(3): 196-204 (2009).
159. Lu KP. Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem Sci 29(4): 200-9 (2004).
160. van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW, et al. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40(1-2): 11-5 (2005).
161. Maruszak A, Safranow K, Gustaw K, Kijanowska-Haladyna B, Jakubowska K, Olszewska M, et al. PIN1 gene variants in Alzheimer's disease. BMC Med Genet 10(115 (2009).
162. Thinnes FP. Why cancer survivors have a lower risk of Alzheimer disease. Mol Genet Metab 107(3): 630-1 (2012).
163. Tirumalasetti F, Han L, Birkett DP. The relationship between cancer and Alzheimer's disease. J Am Geriatr Soc 39(8): 840 (1991).
164. Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 344: e1442 (2012).
165. Brenner DE, Kukull WA, van Belle G, Bowen JD, McCormick WC, Teri L, et al. Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. Neurology 43(2): 293-300 (1993).
166. Tyas SL. Are tobacco and alcohol use related to Alzheimer's disease? A critical assessment of the evidence and its implications. Addict Biol 1(3): 237-54 (1996).
167. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 13(4): 131-44 (1994).
168. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 351(9119): 1840-3 (1998).
169. Rusanen M, Kivipelto M, Quesenberry CP, Jr., Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 171(4): 333-9 (2011).
170. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 166(4): 367-78 (2007).
171. Cataldo JK, Prochaska JJ, Glantz SA. Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 19(2): 465-80 (2010).
172. Rusanen M, Rovio S, Ngandu T, Nissinen A, Tuomilehto J, Soininen H, et al. Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer's disease: a population-based cardiovascular risk factors, aging and dementia study. Dement Geriatr Cogn Disord 30(3): 277-84 (2010).
173. Harwood DG, Kalechstein A, Barker WW, Strauman S, St George-Hyslop P, Iglesias C, et al. The effect of alcohol and tobacco consumption, and apolipoprotein E genotype, on the age of onset in Alzheimer's disease. Int J Geriatr Psychiatry 25(5): 511-8 (2010).
174. Ruitenberg A, van Swieten JC, Witteman JC, Mehta KM, van Duijn CM, Hofman A, et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 359(9303): 281-6 (2002).
175. Huang W, Qiu C, Winblad B, Fratiglioni L. Alcohol consumption and incidence of dementia in a community sample aged 75 years and older. J Clin Epidemiol 55(10): 959-64 (2002).
176. Larrieu S, Letenneur L, Helmer C, Dartigues JF, Barberger-Gateau P. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging 8(3): 150-4 (2004).
177. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156(5): 445-53 (2002).
178. Peters R, Peters J, Warner J, Beckett N, Bulpitt C. Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 37(5): 505-12 (2008).
179. Garcia AM, Ramon-Bou N, Porta M. Isolated and joint effects of tobacco and alcohol consumption on risk of Alzheimer's disease. J Alzheimers Dis 20(2): 577-86 (2010).
180. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 319(7224): 1523-8 (1999).
181. Belleville J. The French paradox: possible involvement of ethanol in the protective effect against cardiovascular diseases. Nutrition 18(2): 173-7 (2002).
182. Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P, Marambaud P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci 9 Suppl 2(S6 (2008).
183. Anttila T, Helkala EL, Viitanen M, Kareholt I, Fratiglioni L, Winblad B, et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ 329(7465): 539 (2004).
184. Paul CA, Au R, Fredman L, Massaro JM, Seshadri S, Decarli C, et al. Association of alcohol consumption with brain volume in the Framingham study. Arch Neurol 65(10): 1363-7 (2008).
185. Hulse GK, Lautenschlager NT, Tait RJ, Almeida OP. Dementia associated with alcohol and other drug use. Int Psychogeriatr 17 (1): S109-27 (2005).
186. Prasanthi JR, Dasari B, Marwarha G, Larson T, Chen X, Geiger JD, et al. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic Biol Med 49(7): 1212-20 (2010).
187. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, et al. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 17(3): 681-97 (2009).
188. Chen X, Ghribi O and Geiger JD. Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis 20(1): S127-41 (2010).
189. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142(4): 941-52 (2006).
190. Cao C, Wang L, Lin X, Mamcarz M, Zhang C, Bai G, et al. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice. J Alzheimers Dis 25(2): 323-35 (2011).
191. Gelber RP, Petrovitch H, Masaki KH, Ross GW, White LR. Coffee intake in midlife and risk of dementia and its neuropathologic correlates. J Alzheimers Dis 23(4): 607-15 (2011).
192. Laitala VS, Kaprio J, Koskenvuo M, Raiha I, Rinne JO, Silventoinen K. Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr 90(3): 640-6 (2009).
193. Eskelinen MH, Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer's disease. J Alzheimers Dis 20(1): S167-74 (2010).
194. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 16(1): 85-91 (2009).
195. Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis 30(3): 559-72 (2012).
196. Santos C, Lunet N, Azevedo A, de Mendonca A, Ritchie K, Barros H. Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal. J Alzheimers Dis 20(1): S175-85 (2010).
197. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis 20(1): S187-204 (2010).
198. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 12(5): e426-37 (2011).
199. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT, Jr., et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 66(3): 336-42 (2009).
200. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Jr., Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330(7504): 1360 (2005).
201. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 76(18): 1568-74 (2011).
202. Ho AJ, Raji CA, Becker JT, Lopez OL, Kuller LH, Hua X, et al. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging 31(8): 1326-39 (2010).
203. Doruk H, Naharci MI, Bozoglu E, Isik AT, Kilic S. The relationship between body mass index and incidental mild cognitive impairment, Alzheimer's disease and vascular dementia in elderly. J Nutr Health Aging 14(10): 834-8 (2010).
204. Hughes TF, Borenstein AR, Schofield E, Wu Y, Larson EB. Association between late-life body mass index and dementia: The Kame Project. Neurology 72(20): 1741-6 (2009).
205. Chu LW, Tam S, Lee PW, Yik PY, Song Y, Cheung BM, et al. Late-life body mass index and waist circumference in amnestic mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 17(1): 223-32 (2009).
206. Vidoni ED, Townley RA, Honea RA, Burns JM. Alzheimer disease biomarkers are associated with body mass index. Neurology 77(21): 1913-20 (2011).
207. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 144(2): 73-81 (2006).
208. Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 78(17): 1323-9 (2012).
209. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 39(1): 3-11 (2009).
210. Scarmeas N, Luchsinger JA, Brickman AM, Cosentino S, Schupf N, Xin-Tang M, et al. Physical activity and Alzheimer disease course. Am J Geriatr Psychiatry 19(5): 471-81 (2011).
211. Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, et al. Physical activity and amyloid-beta plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol Psychiatry 18(8): 875-81 (2013).
212. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 25(6): 295-301 (2002).
213. Pietropaolo S, Sun Y, Li R, Brana C, Feldon J, Yee BK. The impact of voluntary exercise on mental health in rodents: a neuroplasticity perspective. Behav Brain Res 192(1): 42-60 (2008).
214. van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci 2(3): 266-70 (1999).
215. Garcia-Mesa Y, Lopez-Ramos JC, Gimenez-Llort L, Revilla S, Guerra R, Gruart A, et al. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice. J Alzheimers Dis 24(3): 421-54 (2011).
216. Stranahan AM, Martin B, Maudsley S. Anti-inflammatory effects of physical activity in relationship to improved cognitive status in humans and mouse models of Alzheimer's disease. Curr Alzheimer Res 9(1): 86-92 (2012).
217. Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 4(11): 705-11 (2005).
218. Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O'Neil JP, et al. Association of Lifetime Cognitive Engagement and Low beta-Amyloid Deposition. Arch Neurol 69(5): 623-29 (2012).
219. Wilson RS, Scherr PA, Schneider JA, Tang Y, Bennett DA. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology 69(20): 1911-20 (2007).
220. Sattler C, Toro P, Schonknecht P, Schroder J. Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. Psychiatry Res 196(1): 90-5 (2012).
221. Akbaraly TN, Portet F, Fustinoni S, Dartigues JF, Artero S, Rouaud O, et al. Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology 73(11): 854-61 (2009).
222. Stern C, Munn Z. Cognitive leisure activities and their role in preventing dementia: a systematic review. Int J Evid Based Healthc 8(1): 2-17 (2010).